skip to content
Subcutaneous immunotherapy for the treatment of allergies : a review of the clinical efficacy, safety and guidelines Preview this item
ClosePreview this item
Checking...

Subcutaneous immunotherapy for the treatment of allergies : a review of the clinical efficacy, safety and guidelines

Author: Canadian Agency for Drugs and Technologies in Health.
Publisher: [Ottawa, Ont.] : Canadian Agency for Drugs and Technologies in Health, 2012.
Series: Rapid response report.
Edition/Format:   eBook : Document : English
Database:WorldCat
Summary:
Subcutaneous immunotherapy (SCIT) was introduced a century ago. It represents for the third most important mainstay offered to allergic patients and is currently the only means of altering the abnormal immune response that underlies allergic disease. SCIT involves the gradual administration of increasing amounts of allergen to induce protective immunologic responses over a period of three to five years. The  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health.
OCLC Number: 818083740
Notes: "24 July 2012."
Description: 1 online resource (31 pages) : tables, digital file.
Contents: Pages:1 to 10; Pages:11 to 20; Pages:21 to 30; Pages:31 to 31.
Series Title: Rapid response report.
Responsibility: [prepared by Canadian Agency for Drugs and Technologies in Health].
More information:

Abstract:

Subcutaneous immunotherapy (SCIT) was introduced a century ago. It represents for the third most important mainstay offered to allergic patients and is currently the only means of altering the abnormal immune response that underlies allergic disease. SCIT involves the gradual administration of increasing amounts of allergen to induce protective immunologic responses over a period of three to five years. The beneficial effects are usually seen within the first year of treatment. The mechanisms of action of SCIT are multiple and complex. The allergens that are known to be effective for use in SCIT include several tree, grass, and weed pollens, cat and dog dander, dust mites, certain molds, and cockroaches. The allergen used could be single or mixture of multiple allergens. There is no standard approach for the specific allergens or dose schedule to guide clinical practice. Although SCIT is used worldwide, sublingual immunotherapy (SLIT) has been conducted with single allergen extracts more recently. SLIT is considered a viable alternative to SCIT and is used in many areas of Europe, Latin America, and Asia. SLIT has not been approved by the U.S. Food and Drug Administration for use in the United States. The purpose of this report to review the evidence of comparative clinical effectiveness and safety profile of SCIT compared with antihistamine, SLIT or placebo in patients with allergy diseases and identify the existing guidelines on SCIT in the treatment of allergy diseases.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/818083740> # Subcutaneous immunotherapy for the treatment of allergies : a review of the clinical efficacy, safety and guidelines
    a schema:MediaObject, schema:CreativeWork, schema:Book ;
    library:oclcnum "818083740" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/1181780699#Place/ottawa_ont> ; # Ottawa, Ont.
    schema:about <http://experiment.worldcat.org/entity/work/data/1181780699#Topic/desensitization_immunologic> ; # Desensitization, Immunologic
    schema:about <http://experiment.worldcat.org/entity/work/data/1181780699#Topic/allergy_desensitization> ; # Allergy desensitization
    schema:about <http://experiment.worldcat.org/entity/work/data/1181780699#Topic/immunotherapy> ; # Immunotherapy
    schema:about <http://dewey.info/class/616.9706/e23/> ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://viaf.org/viaf/145374402> ; # Canadian Agency for Drugs and Technologies in Health.
    schema:datePublished "2012" ;
    schema:description "Subcutaneous immunotherapy (SCIT) was introduced a century ago. It represents for the third most important mainstay offered to allergic patients and is currently the only means of altering the abnormal immune response that underlies allergic disease. SCIT involves the gradual administration of increasing amounts of allergen to induce protective immunologic responses over a period of three to five years. The beneficial effects are usually seen within the first year of treatment. The mechanisms of action of SCIT are multiple and complex. The allergens that are known to be effective for use in SCIT include several tree, grass, and weed pollens, cat and dog dander, dust mites, certain molds, and cockroaches. The allergen used could be single or mixture of multiple allergens. There is no standard approach for the specific allergens or dose schedule to guide clinical practice. Although SCIT is used worldwide, sublingual immunotherapy (SLIT) has been conducted with single allergen extracts more recently. SLIT is considered a viable alternative to SCIT and is used in many areas of Europe, Latin America, and Asia. SLIT has not been approved by the U.S. Food and Drug Administration for use in the United States. The purpose of this report to review the evidence of comparative clinical effectiveness and safety profile of SCIT compared with antihistamine, SLIT or placebo in patients with allergy diseases and identify the existing guidelines on SCIT in the treatment of allergy diseases."@en ;
    schema:description "Pages:1 to 10; Pages:11 to 20; Pages:21 to 30; Pages:31 to 31."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/1181780699> ;
    schema:genre "Electronic books"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/1181780699#Series/rapid_response_report_summary_with_critical_appraisal> ; # Rapid response report, summary with critical appraisal
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/1181780699#Series/rapid_response_report> ; # Rapid response report.
    schema:name "Subcutaneous immunotherapy for the treatment of allergies : a review of the clinical efficacy, safety and guidelines"@en ;
    schema:productID "818083740" ;
    schema:publication <http://www.worldcat.org/title/-/oclc/818083740#PublicationEvent/ottawa_ont_canadian_agency_for_drugs_and_technologies_in_health_2012> ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/1181780699#Agent/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health
    schema:url <http://public.eblib.com/choice/publicfullrecord.aspx?p=3282807> ;
    schema:url <http://www.deslibris.ca/ID/234394> ;
    schema:url <http://site.ebrary.com/id/10611131> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/818083740> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/1181780699#Agent/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health
    a bgn:Agent ;
    schema:name "Canadian Agency for Drugs and Technologies in Health" ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780699#Series/rapid_response_report> # Rapid response report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/818083740> ; # Subcutaneous immunotherapy for the treatment of allergies : a review of the clinical efficacy, safety and guidelines
    schema:name "Rapid response report." ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780699#Series/rapid_response_report_summary_with_critical_appraisal> # Rapid response report, summary with critical appraisal
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/818083740> ; # Subcutaneous immunotherapy for the treatment of allergies : a review of the clinical efficacy, safety and guidelines
    schema:name "Rapid response report, summary with critical appraisal" ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780699#Topic/allergy_desensitization> # Allergy desensitization
    a schema:Intangible ;
    schema:name "Allergy desensitization"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780699#Topic/desensitization_immunologic> # Desensitization, Immunologic
    a schema:Intangible ;
    schema:name "Desensitization, Immunologic"@en ;
    .

<http://viaf.org/viaf/145374402> # Canadian Agency for Drugs and Technologies in Health.
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health." ;
    .

<http://www.worldcat.org/title/-/oclc/818083740>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/818083740> ; # Subcutaneous immunotherapy for the treatment of allergies : a review of the clinical efficacy, safety and guidelines
    schema:dateModified "2017-09-18" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.